💬 Catch @JackCastle, Head of Corporate Development & Business Operations, at @BPatientCap x @CooleyLLP Biotech CEO Event. He'll share insights from Ochre Bio’s deal-making journey. 🕓 4pm – Arrival 🎤 4:15pm – Deal Spotlight interview 🤝 6pm – Networking #TeamOchre

MASH affects 1.5-6.45% of the global population. Great to see our name in this @NatureBiotech article, highlighting how some innovative biotechs are helping uncover the molecular mechanisms underpinning this underserved disease ➡️ https://t.co/kuteFussq8

🚀 Announcing our new multi-year data license agreement with @GSK to investigate the drivers of #liverdisease! Read the announcement ➡️ https://t.co/KgY2AZVYWI

Screening and disease models in drug R&D generally identify drug candidates then fail to work in people. So @OchreBio had a cunning plan; use real human livers to model real human livers. @Jack_O_Meara

Boehringer announced a new chronic liver disease partnership w/Oxford, UK-based biotech & @ycombinator alum @OchreBio. $35M upfront & near-term payments & up to $1B if milestones met. CEO is @Jack_O_Meara, CSO @QuinWills, @jackcastle is Head of Corporate Development. Congrats!

Super proud of the Ochre and BI teams coming together for this partnership to break ground in an underexplored area of liver biology. Excited about this one! Thanks to BI for welcoming us.

🎉 Announcing our partnership with @Boehringer to develop novel regenerative treatments for chronic #liverdisease, which affects affect millions worldwide! Together we will continue to pioneer liver regeneration research. Full announcement➡️ https://t.co/nZSQEuk34T

We're featured in the #DecodingBio 2023 Snapshot, highlighting the companies shaping the bio landscape. Our mission is to redefine liver medicines – through an approach rooted in #genomics & human models. Check out the report➡️ https://t.co/faz2lsKcg0

On the Decoding Life podcast, our Director of In Silico Biology, Dimitris Polychronopoulos shares how advancements in computational #biology are changing the game in #healthcare. Learn more about how Dimitris is 'cracking life's code' ➡️ https://t.co/RxrCvzHCkd

This week, 5-8th June, @Jack_O_Meara & @jackcastle, will be in Boston USA for the BIO International Convention! They're looking forward to meeting industry leaders, and learning about the breakthroughs & challenges facing the #biotech industry today, Connect with us ⬇️

We are pleased to announce the appointment of Dr @EliotForster as Chairperson of our Board of Directors 🎉 "We look forward to leveraging his extensive leadership experience towards the development of impactful medicines for #liverdisease patients” ➡️ https://t.co/xATBJCGsIX

Catch us onstage at the @LSXLeaders World Congress! 🔸May 3rd, 10.45 – @jackcastle will be discussing our cutting-edge technology in the #TechBio showcase 🔸May 4th, 14:00 – @QuinWills will be taking part in the Diversity & Inclusion in #Biotech and #Pharma panel #TeamOchre

Today we introduce the world-leading experts who have joined our Science Strategy Board. 👇 https://t.co/XIZlU2Ti8z It is truly an honour to have such well respected and renowned advisors working with Ochre Bio. #TeamOchre #advisors #announcement #liver #biotech #liverdisease

Announcing our $30M Series A! HUGE thanks to our amazing transdisciplinary team for enabling this important moment, as we work towards developing therapies to develop new medicines for chronic liver diseases. 👇 https://t.co/JEg11nzRcJ #TeamOchre #biotech #funding #LiverTwitter

Nice write-up in the @FT of the revolutionary work the team @OchreBio are doing in the field of liver disease:

Another coffee chat, and this time with our cell-curious Dr Alice Preston who chats about her experience after switching from academia to industry (and how she likes her coffee of course!). Click below to find out more 👇 https://t.co/fuT5yFlTCz #livertwitter #coffeechats #CELL

At Ochre we say that the liver is the "brain of your metabolism". Educate yourself with wonderful resources like the @LiverTrust, or simply check out these three quick liver facts that @RoryCunningham_ at our NY Organ ICU has put together for you. 👇 #LiverTwitter #liver #rna

Studies found recurrent and de novo NAFLD occurred ~50–70% of all liver transplant recipients in y1 and patients with NASH-related cirrhosis were more likely to die from CVD complications or sepsis post-transplant. https://t.co/IWsdNXUx0j

This review highlights the great unmet need facing patients we hope to treat with our #RNAi medicines for patients receiving liver transplants. See below 👇 https://t.co/mxJABc3Ibe #RNAI #LiverTwitter #liverdisease #chronicillness #NAFLD #NASH

Have a read below where Rory Cunningham, one of our scientists in New York Lab speaks about liver transplants, the current situation and development of different therapies to help fight against different liver diseases like NASH/NAFLD. https://t.co/vIRhGRWVt0 #biotech #Liver